赵粟,李志敏,王鲜
ZHAO Su,LI Zhimin,WANG Xian

• 1:贵州医科大学眼科学教研室
• 2:贵州医科大学附院眼科
• 3:贵州医科大学

摘要(Abstract)：

目的:观察玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性(w AMD)的效果。方法:w AMD患者共38例(38只眼),采用玻璃体腔注射雷珠单抗注射,1次/月,共注射3次;观察注射前、注射后2周、1月、3月的最佳矫正视力(BCVA)以及黄斑中心凹厚度(CFT),同时观察患者眼压、炎症、前房积血、视网膜出血、白内障等术后不良反应及并发症,分析玻璃体腔注射雷珠单抗治疗前、后的情况。结果:治疗后2周、1月及3月BCVA均高于治疗前,并呈升高趋势,而CFT均低于治疗前,并呈下降趋势,差异有统计学意义(P<0.05);无眼内炎、视网膜脱离等严重不良反应及并发症发生。结论:玻璃体腔注射雷珠单抗治疗w AMD起效快疗效显著、副作用小。
Objective: To investigate the curative efficacy of vitreous cavity injection of monoclonal antibody( lucentis) on wet age-related macular degeneration( w AMD). Method: A total of 38 patients with w AMD were given lucentis in vitreous cavity,best corrected visual acuity( BCVA) and macular central foveal thickness( CFT) were observed before operation,two weeks,one month and three months after operation; postoperative adverse reactions and complications such as high intraocular pressure,inflammation,anterior chamber hemorrhage,retinal hemorrhage,cataracts were detected;curative effect was analyzed. Results: Two weeks,1 month and 3 months after treatment,BCVA was higher than that before treatment,and showed rising trend,while CFT was lower than that before treatment,and showed descending trend,the differences were statistically significant( P < 0. 05). There was no serious adverse reaction and complication. Conclusion: Vitreous cavity injection of lucentis shows obvious curative effects and few adverse reactions.

关键词(KeyWords)： 雷珠单抗;黄斑变性;老年人;最佳矫正视力;视力损伤者
lucentis;macular degeneration;elderly people;best corrected visual acuity;visually impaired persons

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 赵粟,李志敏,王鲜
ZHAO Su,LI Zhimin,WANG Xian

DOI: 10.19367/j.cnki.1000-2707.2015.07.023

参考文献(References)：

• [1]Oyer DS,Heier JS,Brown DM,et al.A phase b study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration[J].Ophthalmology,2011(116):1731-1739.
• [2]Zeng QH.Ophthalmology of traditional Chinese Medicine(in Chinese)[M].Beijing:Chinese press of traditional Chinese Medicine,2005:1961.
• [3]郭梦翔,易长贤.AMD的病因研究进展[J].眼科研究,2009(5):557-560.
• [4]Heier JS,Campochiaro PA,Yau L,et al.Ranibizumab for macular edema due to retinal vein occlusions:long-term follow-up in the HORIZON trial[J].Ophthalmology,2012(4):802-809.
• [5]Nguyen QD,Shah SM,Khwaja AA,et al.Two-year outcomes of the ranibizumab for edema of the Macula in diabetes(READ-2)study[J].Ophthalmology,2010(117):2146-2151.
• [6]杨旸,祁勇军,邓建华,等.年龄相关性黄斑变性的治疗研究[J].广东医学,2013(15):2407-2409.
• [7]陈有信,张古沐阳.提高对年龄相关性黄斑变性危险因素的认识[J].中华实验眼科杂志,2012(30):193-198.
• [8]Mc Allister IL,Gillies ME,Smithies LA,et al.The Central Retinal Vein Bypass Study:a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion[J].Ophthalmology,2010(5):954-965.
• [9]Landa G,Amde W,Doshi V,et al.Comparative study of intravitreal bevacizumab versus ranibizumab in the treatment of neovascular age related macular degeneration[J].Ophthalmologica,2009(6):370-375.
• [10]Schmidt-Erfurth U,Eldem B,Guymer R,et al.Efficacy and safety of monthly versus quarterly Lucnetis treatment in neovascular age-related macular degeneration:the EXCITE study[J].Ophthalmology,2013(5):831-839.

文章评论(Comment)：